Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RVK strain 100 (UV-inactivated) is an experimental, non-pathogenic rotavirus-based therapeutic candidate derived from a new, non-classified group of the *Reoviridae* family. Developed by researchers at the Rostov Research Institute of Microbiology and Parasitology, this specific variant is inactivated by ultraviolet (UV) radiation. Unlike the live attenuated version of the strain, which exhibits oncolytic properties, the UV-inactivated strain 100 appears to function primarily through an immunostimulatory mechanism. Preclinical studies in mouse models of B16/F10 melanoma have demonstrated that prophylactic administration (vaccination regimen) can significantly slow tumor growth and improve survival, whereas therapeutic administration after tumor onset is less effective.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RVK strain 100 (UV-inactivated).